

## Suven secures three product patents

01 July 2015 | News | By BioSpectrum Bureau

### Suven secures three product patents



Suven Life Sciences (Suven) announces the grant of one product patent each from Israel (218525), Japan (5714729) and South Africa (2013/09100), corresponding to their New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

With these new patents, Suven has a total of six (6) granted patents from Israel, seventeen (17) granted patents from Japan and twenty (20) granted patents from South Africa. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," said Mr Venkat Jasti, CEO of Suven.